AGA-(C8R) HNG17, Humanin derivative TFA is a potent humanin (HN) derivative. AGA-(C8R) HNG17, Humanin derivative completely suppresses neuronal cell death by Alzheimer's disease-relevant insults.

Gp100 (619-627) acetate is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.

Peptide C105Y TFA, a synthetic and cell-penetrating peptide based on the amino acid sequence corresponding to residues 359-374 of α1-antitrypsin, enhances gene expression from DNA nanoparticles.

Tetanus toxin (830-843) TFA is a powerful neurotoxin that reaches by retroaxonal transport and transcytosis the cytoplasm ofspinal inhibitory intemeurons and blocks their ability to release neurotransmitters.

IRBP (1-20), human TFA contains a major epitope for the H-2b haplotype. IRBP (1-20), human TFA induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.

GRGDSPC TFA, a 7-amino acid peptide, is a thiolated cell adhesion peptide.

LL-37 scrambled peptide acetate is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide acetate can be used as a negative control of LL-37 peptide studies.

Antioxidant peptide A TFA is a short peptide, which contains alternative aromatic or sulfur-containing amino acid. The side chains of Antioxidant peptide A are believed to contribute to strong radical scavenging activities of peptides in the cancer cell.

β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).

Acetyl-pepstatin is a high affinity aspartic protease inhibitor. Acetyl-pepstatin inhibits HIV-1 protease (Ki=20 nM at pH 4.7) and HIV-2 protease (Ki= 5 nM at pH 4.7). Antiviral.

AP 811 is a selective atrial natriuretic peptide clearance receptor (APN-CR, NPR3) antagonist (Ki=0.48 nM). AP 811 displays >20,000-fold selectivity for NPR3 over NPR1. AP 811 abolishes ANP-induced pump stimulation.

GRK2i is a GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. GRK2i corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist.

AC 187 TFA is an orally active, potent amylin receptor antagonist (IC50= 0.48 nM) that displays 38-fold and 400-fold selectivity over calcitonin and CGRP receptors respectively. AC 187 TFA blocks amyloid β-induced neurotoxicity by attenuating the activation of initiator and effector caspases in vitro. AC 187 TFA increases glucagon secretion, accelerates gastric emptying, alters plasma glucose levels and increases food intake in vivo.

AC 187 is an orally active, potent amylin receptor antagonist (IC50= 0.48 nM) that displays 38-fold and 400-fold selectivity over calcitonin and CGRP receptors respectively. AC 187 blocks amyloid β-induced neurotoxicity by attenuating the activation of initiator and effector caspases in vitro. AC 187 increases glucagon secretion, accelerates gastric emptying, alters plasma glucose levels and increases food intake in vivo.

ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP).

ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP).

Neuropeptide S human is a potent endogenous neuropeptide S receptor agonist (EC50= 9.4 nM). Neuropeptide S human increases locomotor activity and wakefulness in mice. Neuropeptide S human also reduces anxiety-like behavior in mice.

Rac1 Inhibitor F56, control peptide TFA is a control peptide version of Rac1 Inhibitor. Rac1 Inhibitor F56, control peptide comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Rac1 Inhibitor F56, control peptide TFA does not affect GEF-Rac1 interaction.

Rac1 Inhibitor F56, control peptide is a control peptide version of Rac1 Inhibitor. Rac1 Inhibitor F56, control peptide comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Rac1 Inhibitor F56, control peptide does not affect GEF-Rac1 interaction.

Amyloid β-Peptide(1-43) human TFA, the Human β-amyloid peptide, is minor component of neuritic plaques found in brains of patients with Alzheimer's disease.

Amyloid β-Peptide(1-43) human, the Human β-amyloid peptide, is minor component of neuritic plaques found in brains of patients with Alzheimer's disease.

des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.

des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.

DAPK Substrate Peptide is a synthetic peptide substrate for death associated protein kinase (DAPK), with a Km of 9 μM.

Prosaptide Tx14(A) TFA, a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC50s of 5 and 7 nM, respectively. Prosaptide Tx14(A) TFA increases both ERK1 and ERK2 phosphorylation in Schwann cells.

Prosaptide Tx14(A), a prosaposin-derived peptide, is a potent GPR37L1 and GPR37 agonist with EC50s of 5 and 7 nM, respectively. Prosaptide Tx14(A) increases both ERK1 and ERK2 phosphorylation in Schwann cells.

LRGILS-NH2 TFA is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.

LRGILS-NH2 is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.

RLLFT-NH2 TFA is a reversed amino acid sequence negative control peptide for TFLLR-NH2.

RLLFT-NH2 is a reversed amino acid sequence negative control peptide for TFLLR-NH2.